{"product_id":"valneva-value-chain-analysis","title":"Valneva Value Chain Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Value Chain Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Valneva Value Chain Analysis gives you a clear, structured view of the company’s support and primary activities, helping you understand how value is created. The page already shows a real preview of the actual analysis, not just promotional text, so you can review the content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eupport Activities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Support-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFirm Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva’s firm infrastructure has to keep R\u0026amp;D, manufacturing, quality, regulatory, and commercial teams aligned across 5 countries, because specialty vaccines depend on tight control from lab to launch. That matters more here than in most pharma models: one delay in QA or filing can slow supply, and capital-heavy vaccine work leaves less room for execution errors.\u003c\/p\u003e\n\u003cp\u003eIn 2025, this structure supports a business built on regulated, cross-border delivery rather than scale alone.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Support-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuman Resource Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva relies on vaccine-specific scientists, clinical teams, manufacturing specialists, and medical affairs staff to keep its pipeline moving. In 2025, that mix matters because GMP quality and regulatory work need tight execution across countries, not just lab skill.\u003c\/p\u003e\n\u003cp\u003eHiring and retention are a real operating lever for Valneva because skilled people are hard to replace fast, and any gap can slow batch release, trials, or market access. One weak link in the team can delay the whole chain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Support-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Support-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva’s technology development turns pathogen-specific research into vaccines that can be made at scale, with work centered on discovery, clinical development, process optimization, and analytical testing. Its pipeline shows that model in practice through one approved product, IXCHIQ, and one late-stage Lyme candidate, VLA15.\u003c\/p\u003e\n\u003cp\u003eThis support activity drives value by reducing technical risk before launch and by improving yield and quality for manufacturing. In 2025, that matters because each step from lab assay to GMP process can shape timing, cost, and regulatory success.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Support-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eValneva’s procurement must lock in antigens, excipients, vials, syringes, cold-chain materials, and outsourced services to exact specs, because any miss can delay batch release and supply for specialty vaccines.\u003c\/p\u003e\n\u003cp\u003eStrong supplier qualification and dual-sourcing cut batch risk, support continuity, and help protect availability when a single input is scarce or fails quality checks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Support-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Support-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValneva’s Lean Backbone Powers IXCHIQ and VLA15 Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva’s support activities stay lean but critical: firm infrastructure, skilled teams, R\u0026amp;D, and procurement must stay aligned across 5 countries to avoid delays in GMP, filings, and batch release. In 2025, that matters because specialty vaccines depend on exact execution, not scale. With one approved product, IXCHIQ, and one late-stage candidate, VLA15, each support step can shape cost, timing, and launch risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved product\u003c\/td\u003e\n\u003ctd\u003eIXCHIQ\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nMaps Valneva’s support and core activities to show how the company creates and delivers value.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nProvides a clear Valneva Value Chain Analysis to quickly identify operational pain points, value drivers, and opportunities across primary and support activities.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003erimary Activities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Primary-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInbound Logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva sources biologic materials, packaging inputs, and clinical or commercial components through GMP-controlled channels, so each inbound lot can be tracked, tested, and released before use. Inbound logistics is a quality gate, not just procurement, because a missed or late material can delay batch timing and push up working capital. In Valneva’s 2025 operations, that tight control supports vaccine supply continuity, inventory planning, and on-time release for regulated markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Primary-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva turns R\u0026amp;D outputs into commercial vaccines through manufacturing, fill-finish, testing, and batch release. In its 2025 fiscal year, this step stayed the main driver of supply reliability, because yield, sterility, and lot consistency shape both delivery risk and gross margin.\u003c\/p\u003e\n\u003cp\u003eOperations also matter because even small process losses can hit vaccine volumes fast, so tight quality control protects cash flow. For a biologics maker like Valneva, that makes each released batch a direct link between science and sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Primary-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Primary-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutbound Logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva’s outbound logistics depends on cold-chain, GDP-compliant distribution so finished vaccines can reach travel clinics, distributors, public buyers, and healthcare providers without losing potency. This network lets Valneva serve multiple markets at once and keep inventories lean, which matters for a portfolio that includes products like IXIARO\/JESPECT and DUKORAL. Good shipment control also lowers write-off risk and supports on-time delivery for time-sensitive vaccine demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Primary-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eValneva sells IXIARO, DUKORAL, and IXCHIQ through specialty channels, public-sector tenders, medical education, and distributor partners, not mass retail. This model fits travel and niche vaccines, where access, reimbursement, and clinician awareness drive uptake more than shelf space. In 2025, that channel mix supports focused promotion and demand generation, but it also makes execution dependent on tender timing and distributor reach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialty channels support niche vaccine demand.\u003c\/li\u003e\n\u003cli\u003ePublic-sector contracts can swing sales timing.\u003c\/li\u003e\n\u003cli\u003eEducation drives awareness and reimbursement access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Primary-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eService\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eValneva's service layer is post-sale pharmacovigilance, medical information, safety monitoring, and supply support. In vaccines, this work keeps trust intact with regulators and clinicians, and it helps Valneva defend long-cycle demand after launch.\u003c\/p\u003e\n\u003cp\u003eIt also reduces risk of supply gaps and faster escalations on adverse-event cases, which matters in a field where safety data can shape renewal, tender, and stock decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Primary-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValneva’s 2025 Vaccine Supply Chain: Precision, Quality, and Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn fiscal 2025, Valneva’s primary activities stayed centered on GMP manufacturing, fill-finish, testing, and batch release, where yield and sterility control directly shape supply and gross margin. Outbound logistics used cold-chain, GDP-compliant delivery to protect IXIARO\/JESPECT, DUKORAL, and IXCHIQ potency across clinics, distributors, and public buyers. Sales relied on specialty channels, tenders, and medical education, so timing and access drove demand more than retail shelf space.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eValneva Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the actual Valneva Value Chain Analysis document, not a sample. The content below is taken directly from the full report, so the structure and quality are exactly what you’ll receive. After purchase, the complete version is unlocked for immediate access. No surprises—just the full professional analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53670069993814,"sku":"valneva-value-chain-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/valneva-value-chain-analysis.webp?v=1778902157","url":"https:\/\/balancedscorecardexamples.com\/products\/valneva-value-chain-analysis","provider":"Balanced Scorecard","version":"1.0","type":"link"}